STOCKS TELEGRAPH

Tag: AZRX stock

  • AzurRx BioPharma, Inc. (AZRX) Stock Suffers Following Upsizing of Previously Announced Public Offering

    AzurRx BioPharma, Inc. (AZRX) stock prices were down 19.66% as of the market closing on July 23rd, 2021, bringing the price per share down to USD$0.5690. Subsequent premarket fluctuations saw the stock rally by 12.48%, bringing it up to USD$0.64.

    AZRX Upsizes Offering

    July 22nd, 2021 saw AZRX stock announce the increasing of the size of its previously announced public offering because of unexpected demand. The underwriter has agreed to purchase on a firm commitment basis 9,090,910 shares of common stock of the company. The price was the same as the public offering, with each share being priced at USD$0.55. The closing of the transaction is expected for July 27th, 2021.

    Details of the Offering

    the offering comes equipped with a 30-day option to purchase up to an additional 1,363,636 shares of common stock at the same public offering price. AZRX stock expects generating USD$5 million in gross proceeds before the deduction of expenses related to the offering and the execution of the option to purchase additional shares. The capital raised is expected to be used to pay milestone payments as per existing license agreements.

    AZRX Stock Hits RESERVOIR Milestone

    Earlier on June 7th, 2021, AZRX stock announced the administration of the first dose of FW-1022 to a volunteer in its ongoing Phase 2 RESERVOIR clinical trial. The proprietary treatment comes in tablet form and is designed to treat Covid-19-related GI infections. The company forecasts topline results from the trial for the first quarter of 2022. This development marks a significant milestone for the company and the development of niclosamide.

    Scope of FW-1022

    With no existing approved treatments for GI infections stemming from Covid-19, the success of AZRX’s development program could help prevent reinfection and, therefore, the spread of Covid-19. FW-1022 also has the potential to treat severe complications that are believed to results from SARS-CoV-2’s ability to hide in reservoirs within the GI tract. The company is confident that its micronized oral niclosamide therapy can target the virus directly in the gut. This will play a critical role in the treatment of Covid-19 patients that suffer from the damage caused by Covid-19-related GI infection.

    Future Outlook for AZRX

    With the world hurtling towards universal immunizations, AZRX stock is poised to capitalize on the burgeoning market. Keen to continue its trajectory of success, the company plans to regain momentum with its added capital and reverse the recent downward trend. Investors are confident in management’s ability to produce significant and sustained increases in shareholder value.

  • Why AzurRx BioPharma Inc. (AZRX) stock plummeted on Thursday?

    AzurRx BioPharma Inc. (AZRX) stock declined 16.03% in after-hours on Thursday, July 22, 2021. The stock closed at $0.59 per share. Before that in the morning session, the share price of the Company lost 4.27% to close Thursday’s session at $0.71. AZRX stock has fallen 38.42% over the last 12 months, and they have moved down 0.06% in the past week. Over the past three months, the stock has lost 15.29%, while over the past six months, it has slid down 42.89%.

    Let’s see is there any recent development behind its plummeting on Thursday?

    AZRX stock expanding the previously announced public offering

    On July 22, 2021, AzurRx BioPharma, Inc announced that the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9,090,910 shares of common stock of the Company, at a price to the public of $0.55 per share, due to high demand. The offer will close on July 27, 2021, subject to satisfaction of customary closing conditions.

    Participation in the recent conferences

    • The Chief Executive Officer of AzurRx, James Sapirstein recently presented the company at the 2021 BIO Digital virtual conference which took place on June 10-11 and June 14-18, 2021.
    • The company also participated in the Rocky Mountain Microcap conference which was held on May 26, 2021.MrSapirstein provided an overview of AzurRx’s business and clinical development programs and discussed anticipated 2021 and early 2022 milestones in the conference.

    First Patient dosed in Phase 2 Clinical Trial of Niclosamide

    On June 07, 2021, AzurRx BioPharma, Inc administered the first dose of FW-1022 to a volunteer in the ongoing Phase 2 RESERVOIR clinical trial. FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections. Topline results from the trial are expected in the first quarter of 2022.

    AZRX stock revealed positive interim data from the phase 2 trial of MS1819 

    On May 13, 2021, AZRX stock announced positive interim data from the first 18 out of 20 patients in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).

    The interim data showed that the combination therapy led to clinically meaningful improvements in the primary efficacy endpoint, the Coefficient of Fat Absorption (CFA), with an average gain of 5.9 points from baseline.

    French Research Tax Credit

    On May 12, 2021, AzurRx SAS, which is a wholly-owned subsidiary of AzurRx BioPharma in France, received approximately 459,000 Euros ($550,000 U.S.) in non-dilutive funding in research tax credits from the French government for its 2020 CIR (French Research Tax Credit).

    Conclusion

    The AZRX stock plummeted after the company announced to increase in the size of its previously announced public offering. we are not sure how the stock market will react on Friday for AZRX.

  • AzurRx BioPharma Inc. (AZRX) stock gains in the pre-market trading. Here’s to know why?

    AzurRx BioPharma Inc. (AZRX) stock gains in the pre-market trading. Here’s to know why?

    AzurRx BioPharma Inc. (AZRX) stock declined by 3.92% at the last trading close whereas the AZRX stock gains by 2.04% in the pre-market trading after AZRX announced that they have started their Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide. AzurRx BioPharma is a clinical-stage biopharmaceutical company focused on developing non-systemic, therapeutic strategies for gastrointestinal (GI) diseases.

    What is happening?

    Today AzurRx BioPharma announced that it has started the RESERVOIR Phase 2 clinical trial of a proprietary oral formulation of micronized niclosamide for the prevention of COVID-19-related GI infections. Patient registration is set to begin in April 2021, with topline results expected in the first quarter of 2022.

    The RESERVOIR Phase 2 clinical trial of AZRX stock is a two-part, two-arm, placebo-controlled study that looks at the safety and effectiveness of micronized oral niclosamide tablets, also known as FW-1022, in patients with COVID-19 GI infection. The primary goals of this study would be to confirm the safety of niclosamide in the treatment of COVID-19 GI infection in patients and also to show that it has the ability to clear the SARS-CoV-2 virus from the GI tract.

    The rate of fecal SARS-CoV-2 virus clearance (rectal swab or stool sample) measured by RT-PCR in the RESERVOIR trial is the primary efficacy indicator, with the niclosamide arm compared to the placebo arm for up to six months. These long-term data suggest that niclosamide treatment can help with COVID-19 symptoms in the long run.

    Furthermore,

    The Chief Medical Officer of AzurRx, Dr. James Pennington said that Long-haul COVID cases are becoming a big problem around the world, and it’s fair to believe the GI tract may be acting as a silent reservoir. Because of its validated safety profile, known efficacy in treating other GI ailments, and exceptional ability to stay in the gut for extended periods of time, the team at AZRX stock assumes that niclosamide is ideally suited to remove these secret GI SARS-CoV-2 reservoirs. AZRX’s micronized niclosamide formulation, which allows for localized concentrations in the gutwill enhance these properties.